Zacks Investment Research News Agency
2 days ago•Zacks Investment Research
Stocks Medium Importance Neutral
Gilead Sciences (GILD) Reports Q2 Loss, Beats Revenue Estimates

Gilead Sciences (GILD) Reports Q2 Loss, Beats Revenue Estimates

Gilead Sciences (GILD) came out with a quarterly loss of $6.75 per share versus the Zacks Consensus Estimate of a loss of $7.07. This compares to earnings of $2.01 per share a year ago.

Related Symbols 1
GILD GILD
Source: Zacks Investment Research
Visit Source
0 0 0
Comment

Comments

0
No comments yet
Be the first person to comment on this news item.